These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 25557371

  • 1. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
    Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ, DEFINE and CONFIRM study investigators.
    Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
    Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC.
    Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [Abstract] [Full Text] [Related]

  • 4. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E.
    Clin Ther; 2015 Nov 01; 37(11):2543-51. PubMed ID: 26526385
    [Abstract] [Full Text] [Related]

  • 5. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL.
    Eur J Neurol; 2017 May 01; 24(5):726-733. PubMed ID: 28328179
    [Abstract] [Full Text] [Related]

  • 6. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
    Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT.
    J Neurol; 2014 Sep 01; 261(9):1794-802. PubMed ID: 24989666
    [Abstract] [Full Text] [Related]

  • 7. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.
    Clin Ther; 2014 Dec 01; 36(12):1958-1971. PubMed ID: 25315404
    [Abstract] [Full Text] [Related]

  • 8. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
    Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT, CONFIRM study investigators.
    Neurology; 2015 Mar 17; 84(11):1145-52. PubMed ID: 25681448
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.
    Mult Scler; 2017 Feb 17; 23(2):253-265. PubMed ID: 27207449
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
    Hutchinson M, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E, O'Gorman J, Zhang R, Novas M, Viglietta V, Dawson KT.
    J Neurol; 2013 Sep 17; 260(9):2286-96. PubMed ID: 23749293
    [Abstract] [Full Text] [Related]

  • 11. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
    Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT.
    J Neurol; 2014 Dec 17; 261(12):2429-37. PubMed ID: 25270680
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
    Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson KT.
    J Neurol; 2013 Sep 17; 260(9):2297-305. PubMed ID: 23797999
    [Abstract] [Full Text] [Related]

  • 13. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S, Mikulskis A, Gold R, Fox RJ, Dawson KT, Amaravadi L.
    Mult Scler; 2017 Dec 17; 23(14):1875-1883. PubMed ID: 28156185
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
    Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R.
    Ann Clin Transl Neurol; 2015 Feb 17; 2(2):103-18. PubMed ID: 25750916
    [Abstract] [Full Text] [Related]

  • 15. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 16. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
    O'Gorman J, Russell HK, Li J, Phillips G, Kurukulasuriya NC, Viglietta V.
    Clin Ther; 2015 Jul 01; 37(7):1402-1419.e5. PubMed ID: 25999183
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016 Jul 01; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

  • 18. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J, Rózsa C.
    Ideggyogy Sz; 2015 Jan 30; 68(1-2):7-14. PubMed ID: 25842911
    [Abstract] [Full Text] [Related]

  • 19. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
    Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL.
    Neurol Ther; 2016 Jun 30; 5(1):45-57. PubMed ID: 26932146
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP.
    Clin Ther; 2018 Dec 30; 40(12):2077-2087. PubMed ID: 30470580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.